Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
How Myeloid Mutations in ALL Inform Treatment Decisions
How Genetic Testing Guides Personalized mBC Care
Alexandria May, PharmD, BCPS
Marie Wood, MD
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Chandrikha Chandrasekharan, MBBS
Redefining Cancer Care with Functional Precision Medicine
Matt Birnholz, MD
Jim Foote, MBA
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Guru P. Sonpavde, MD
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Pooja Ghatalia, MD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Ryan Quigley
Amanda Winters, MD, PhD
Tracking Early Immunotherapy Response in mTNBC Using cfDNA-Based Copy-Number Profiling
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Kathrin M. Bernt, MD
Rushabh Mehta, BS
Fatemeh Alikarami
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Victoria Coleman-Cowger, PhD
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Paola Marignani, PhD, EMBA
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.